These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

765 related items for PubMed ID: 29398546

  • 1. Initiation and continuation of oral anticoagulant prescriptions for stroke prevention in non-valvular atrial fibrillation: A cohort study in primary care in France.
    Collings SL, Vannier-Moreau V, Johnson ME, Stynes G, Lefèvre C, Maguire A, Asmar J, Bizouard G, Duhot D, Mouquet F, Fauchier L.
    Arch Cardiovasc Dis; 2018 May; 111(5):370-379. PubMed ID: 29398546
    [Abstract] [Full Text] [Related]

  • 2. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
    Collings SL, Lefèvre C, Johnson ME, Evans D, Hack G, Stynes G, Maguire A.
    PLoS One; 2017 May; 12(10):e0185642. PubMed ID: 29016695
    [Abstract] [Full Text] [Related]

  • 3. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G, Billionnet C, Alla F, Gagne JJ, Pariente A.
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [Abstract] [Full Text] [Related]

  • 4. Apixaban in the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: Rationale and design of the PAROS cross-sectional study.
    Picard F, Ducrocq G, Danchin N, Falissard B, Hanon O, Mahe I, Touzé E, Steg PG.
    Arch Cardiovasc Dis; 2018 May; 111(5):349-356. PubMed ID: 29191525
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB.
    BMJ; 2017 Feb 10; 356():j510. PubMed ID: 28188243
    [Abstract] [Full Text] [Related]

  • 6. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI, Peacock WF, Bunz TJ, Alberts MJ.
    Stroke; 2017 Aug 10; 48(8):2142-2149. PubMed ID: 28655814
    [Abstract] [Full Text] [Related]

  • 7. Adherence and outcomes to direct oral anticoagulants among patients with atrial fibrillation: findings from the veterans health administration.
    Borne RT, O'Donnell C, Turakhia MP, Varosy PD, Jackevicius CA, Marzec LN, Masoudi FA, Hess PL, Maddox TM, Ho PM.
    BMC Cardiovasc Disord; 2017 Sep 02; 17(1):236. PubMed ID: 28865440
    [Abstract] [Full Text] [Related]

  • 8. Apixaban for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation in France: The PAROS cross-sectional study of routine clinical practice.
    Falissard B, Picard F, Mahe I, Hanon O, Touzé E, Danchin N, Lamy FX, Ricci L, Steg PG.
    Arch Cardiovasc Dis; 2019 Sep 02; 112(6-7):400-409. PubMed ID: 31014991
    [Abstract] [Full Text] [Related]

  • 9. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants.
    Halvorsen S, Ghanima W, Fride Tvete I, Hoxmark C, Falck P, Solli O, Jonasson C.
    Eur Heart J Cardiovasc Pharmacother; 2017 Jan 02; 3(1):28-36. PubMed ID: 27680880
    [Abstract] [Full Text] [Related]

  • 10. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY, Mitchell SA, Liu X, Liu LZ, Phatak H, Kachroo S, Batson S.
    Int J Cardiol; 2016 Feb 01; 204():88-94. PubMed ID: 26655548
    [Abstract] [Full Text] [Related]

  • 11. Comparative safety and effectiveness of dabigatran vs. rivaroxaban and apixaban in patients with non-valvular atrial fibrillation: a retrospective study from a large healthcare system.
    Villines TC, Ahmad A, Petrini M, Tang W, Evans A, Rush T, Thompson D, Oh K, Schwartzman E.
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr 01; 5(2):80-90. PubMed ID: 30500885
    [Abstract] [Full Text] [Related]

  • 12. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA.
    J Am Heart Assoc; 2016 Jun 13; 5(6):. PubMed ID: 27412905
    [Abstract] [Full Text] [Related]

  • 13. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban.
    Tepper PG, Mardekian J, Masseria C, Phatak H, Kamble S, Abdulsattar Y, Petkun W, Lip GYH.
    PLoS One; 2018 Jun 13; 13(11):e0205989. PubMed ID: 30383768
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
    Hernandez I, Zhang Y, Saba S.
    Am J Cardiol; 2017 Nov 15; 120(10):1813-1819. PubMed ID: 28864318
    [Abstract] [Full Text] [Related]

  • 15. Appropriateness of initial dose of non-vitamin K antagonist oral anticoagulants in patients with non-valvular atrial fibrillation in the UK.
    García Rodríguez LA, Martín-Pérez M, Vora P, Roberts L, Balabanova Y, Brobert G, Fatoba S, Suzart-Woischnik K, Schaefer B, Ruigomez A.
    BMJ Open; 2019 Sep 20; 9(9):e031341. PubMed ID: 31542760
    [Abstract] [Full Text] [Related]

  • 16. Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
    Palamaner Subash Shantha G, Bhave PD, Girotra S, Hodgson-Zingman D, Mazur A, Giudici M, Chrischilles E, Vaughan Sarrazin MS.
    Circ Cardiovasc Qual Outcomes; 2017 Apr 20; 10(4):. PubMed ID: 28408716
    [Abstract] [Full Text] [Related]

  • 17. Medium- to long-term persistence with non-vitamin-K oral anticoagulants in patients with atrial fibrillation: Australian experience.
    Simons LA, Ortiz M, Freedman B, Waterhouse BJ, Colquhoun D.
    Curr Med Res Opin; 2017 Jul 20; 33(7):1337-1341. PubMed ID: 28425296
    [Abstract] [Full Text] [Related]

  • 18. [One-year persistence of patients already treated with oral anticoagulants for atrial fibrillation].
    Simonyi G, Ferenci T, Finta E, Gasparics R, Medvegy M.
    Orv Hetil; 2019 Mar 20; 160(13):509-515. PubMed ID: 30907102
    [Abstract] [Full Text] [Related]

  • 19. Factors associated with non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with new-onset atrial fibrillation: Results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II (ORBIT-AF II).
    Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Hylek E, Kowey PR, Mahaffey KW, O'Brien EC, Singer DE, Peterson ED, Piccini JP, Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators and Patients.
    Am Heart J; 2017 Jul 20; 189():40-47. PubMed ID: 28625380
    [Abstract] [Full Text] [Related]

  • 20. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention in Incident, Treatment-Naïve Nonvalvular Atrial Fibrillation.
    Brown JD, Shewale AR, Talbert JC.
    J Manag Care Spec Pharm; 2016 Nov 20; 22(11):1319-1329. PubMed ID: 27783556
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.